- Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancerBistrovic Andrea; Krstulovic Luka; Harej Anja; Grbcic Petra; Sedic Mirela; Kostrun Sanja; Pavelic Sandra Kraljevic; Bajic Miroslav; Raic Malic SilvanaEuropean Journal of Medicinal Chemistry, 2018, 143: 1616-1634.
- Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutationsDuan, Jianchun; Zhao, Jun; Zhang, Li; Liu, Baogang; Ren, Xiubao; Li, Mingjun; Shen, Bo; Miao, Liyun; Dai, Xiumei; Pan, Yueyin; Li, Yupin; Yao, Yu; Yang, Kunyu; Wu, Lin; Zhou, Chengzhi; Yu, Qitao; Xie, Yanyan; Zeng, Shan; Wang, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
期刊论文
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers
3被引8阅读
